A pivotal phase III trial of edasalonexent in ambulatory patients with Duchenne Muscular Dystrophy regardless of mutation type

Trial Profile

A pivotal phase III trial of edasalonexent in ambulatory patients with Duchenne Muscular Dystrophy regardless of mutation type

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Edasalonexent (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 According to a Catabasis Pharmaceuticals media release, the company is planning to initiate the trial in first half of 2018.
    • 04 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Jan 2018, according to a Catabasis Pharmaceuticals media release.
    • 30 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top